ArticleFrontiers in medicine2026
Evolution of the NCI antibody-drug conjugate portfolio: from chemical engineering to clinical complexity.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Antibody-drug conjugates (ADCs) have transcended their status as experimental pharmacophores to become a cornerstone of precision oncology. However, the trajectory of federal investment driving this clinical renaissance remains largely unmapped. Understanding the evolution of National Cancer Institute (NCI) funding priorities is critical to identifying how resource allocation has shaped-and must continue to adapt to-the shifting challenges of drug development. Methods: We performed a longitudinal analysis of the NCI grant portfolio spanning 2001 to 2025. To deconstruct the semantic evolution of the field, we employed BERTopic, a transformer-based topic modeling technique. This multi-dimensional approach correlated funding flux with institutional distribution, clinical study designs, and the technical specifications of investigated agents. Results: Our analysis delineates a distinct biphasic growth pattern, where a strategic inflection point in 2016 catalyzed an exponential surge in investment, synchronous with the clinical validation of second-generation platforms. Semantically, the field has undergone a profound structural maturation: research priorities have pivoted from foundational linker chemistry toward addressing the biological complexities of resistance mechanisms and integrating ADCs with immuno-oncology. Despite this translational momentum, we uncover a critical methodological disconnect; Analysis of experimental model systems across the full portfolio reveals that Conclusion: NCI funding has evolved in parallel with the clinical maturation of ADCs. This evolution reflects a bidirectional relationship between public investment and regulatory milestones, in which early FDA approvals catalyzed renewed federal focus on the biological bottlenecks limiting first-generation agents, while the post-2013 portfolio demonstrates a marked emergence of combination therapy and immuno-oncology integration research. However, sustaining this wave of innovation requires a strategic realignment. Future investment must bridge the identified gap in preclinical modeling fidelity, where organoid and 3D culture systems remain markedly underrepresented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.